ClinicalTrials.gg
CompletedNCT05681845Updated Oct 14, 2025

A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge

A Phase 1 interventional study of NNC0365-3769 (Mim8) in Haemophilia A, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Enrollment
5th of 59
205 · median 38
Started
2023
with 2 others
Phase 1
27 of 92
1 open now
Registered
81st of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 5th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2023, is one of 27 in phase 1, and was the 81st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

Novo Nordisk is developing the study medicine Mim8 for the treatment of haemophilia A. The study aims to show similar levels of Mim8 in blood when using a new pen injector, called DV3407-C1 pen injector, and when using a syringe and cartridge. The new pen injector is intended to facilitate the administration of Mim8 for patients with haemophilia A. The participants will get Mim8 as injection under the skin (subcutaneously) of the belly using the DV3407-C1 pen injector and a needle (hereinafter referred to as pen injector) or using a needle and syringe from a cartridge (hereafter called syringe and cartridge). The participants will receive one injection with Mim8, either with the DV3407-C1 pen injector or with a syringe and cartridge. The study participation will last up to 20 weeks. Only healthy men can take part in the study.

03

Conditions studied

  • Haemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male aged 18-55 years (both inclusive) at the time of signing .
  • (BMI) between 18.5 and 29.9 kilogram per square metre (kg/m\^2) (both inclusive) at screening.
  • Body weight between 60.0 and 100.0 kg (both inclusive) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Increased risk of thrombosis, e.g., known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.
  • Factor VIII activity greater than or equal to (≥) 150 percent (%) at screening.
  • Thrombophilia as identified by any of the below laboratory markers at screening:
  • Protein C, protein S or antithrombin less than (\<) lower limit of normal (LLN)
  • Factor II activity or activated protein C resistance > (ULN).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Arm 1 (Pilot part)

    Participants will receive a single dose of Mim8 using a 32G, 4 mm pen-needle with the DV3407-C1 pen injector.

    Drug: NNC0365-3769 (Mim8)

  • Experimental
    Arm 2 (Pilot part)

    Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.

    Drug: NNC0365-3769 (Mim8)

  • Experimental
    Arm 3 (Bioequivalence part)

    Participants will receive a single dose of Mim8 using a 29G, 4 mm pen-needle with the DV3407-C1 pen injector.

    Drug: NNC0365-3769 (Mim8)

  • Experimental
    Arm 4 (Bioequivalence part)

    Participants will receive a single dose of Mim8 using a 29G, 8 mm needle and syringe with the enhanced cartridge.

    Drug: NNC0365-3769 (Mim8)

Interventions

  • Participants will receive a single dose of Mim8 subcutaneously in the abdomen.

06

What researchers measure

Primary outcomes

  1. AUC0-112 days, SD: area under the Mim8 plasma concentration-time curve from time 0 until 112 days after a single dose

    Measured in micrograms\*day per milliliter (μg\*day/mL).

    Time frame: From time of dosing (day 1) to day 113

  2. Cmax, SD: maximum plasma concentration of Mim8 after a single dose

    Measured in μg/mL.

    Time frame: From time of dosing (day 1) to day 113

Secondary outcomes

  1. AUC0-inf, SD: area under the Mim8 plasma concentration-time curve from time 0 to infinity after a single

    Measured in μg\*day/mL.

    Time frame: From time of dosing (day 1) to day 113

  2. t1/2, SD: the terminal half-life of Mim8 after a single dose

    Measured in days.

    Time frame: From time of dosing (day 1) to day 113

  3. tmax, SD: the time to maximum concentration of Mim8 after a single dose

    Measured in days.

    Time frame: From time of dosing (day 1) to day 113

  4. Number of injection site reactions

    Measured in count of events.

    Time frame: From time of dosing (day 1) to day 113

07

Study locations

1 site
  • Charité - Campus Charité Mitte - Charité Research Organisation GmbH
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2023, 9 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 9 months is close to that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2023
First posted
Jan 12, 2023
StartActual
Jan 2, 2023
Primary completionActual
Oct 13, 2023
CompletionActual
Oct 13, 2023
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05681845
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Jan 2, 2023
Primary completion
Oct 13, 2023
Completion
Oct 13, 2023
Last update
Oct 14, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denecimig

Start the discussion